Drug · DIN 02412322
TRELSTAR
MICROGRANULES FOR DEPOT SUSP. 6 MONTH SLOW-RELEASE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 14, 2020; first marketed October 16, 2013.
- Drug Identification Number (DIN)
- 02412322
- Company (DIN owner)
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Powder For Suspension (Sustained-Release
- Route
- Intramuscular
- Therapeutic class (ATC)
- Triptorelin L02AE04
- Class
- Human
- Record last updated
- July 30, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| TRIPTORELIN (TRIPTORELIN PAMOATE) | 22.5 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 2, 2020: NOC 23414New Drug Submission (NDS) · Change of product ownership
- July 13, 2016: NOC 18267New Drug Submission (NDS) · Manufacturer name change
- November 28, 2014: NOC 16374New Drug Submission (NDS) · Transfer of drug identification numbers
- September 11, 2013: NOC 14746Supplement to a New Drug Submission (SNDS) · To support a new formulation of trelstar (triptorelin pamoate for injectable suspension) designed to release 22.5 mg of the active moiety over a period of 168 days (6 month sloww release) for use in the palliative treatment of advanced prostate cancer
Other DINs named TRELSTAR
- DIN 02240000 · Marketed
- DIN 02243856 · Marketed